Navigation Links
Cardiogenesis Reports Third Quarter 2009 Results
Date:11/10/2009

ating loss of $1,577,000 as compared with operating income of $235,000 for the same period in 2008. The net loss for the first nine months of 2009 was $1,643,000 or $0.04 per basic and diluted share, compared with net income of $258,000, or $0.01 per basic and diluted share, for the first nine months of 2008.

Gross margin was 82% of net revenues for the quarters ended September 30, 2009 and 2008. Gross profit decreased by $390,000 to $1,754,000 for the current year third quarter as compared with $2,144,000 for the 2008 third quarter.

For the nine months ended September 30, 2009, gross margin was 82% of net revenues as compared to 84% for the nine months ended September 30, 2008. Gross profit in absolute dollars decreased by $2,215,000 to $5,915,000 for the nine months ended September 30, 2009, as compared to $8,130,000 for the nine months ended September 30, 2008. The decrease in the gross margin percentage for the three months and nine month periods was primarily attributed to a decrease in laser sales.

Research and development expenses were $379,000 in the third quarter of 2009 as compared with $165,000 in the 2008 third quarter. Year to date, R&D expenses of $1,013,000 were $380,000 or 60% above the prior year period of $633,000. The dollar increase for the three month and nine month periods are primarily attributed to regulatory expenses incurred for FDA submissions.

Sales and marketing expenses of $1,363,000 in the quarter ended September 30, 2009 decreased $173,000, or 11%, compared with $1,536,000 for the quarter ended September 30, 2008. For the nine months ended September 30, 2009, sales and marketing expenditures totaled $4,104,000, a decrease of $754,000, or 16%, compared with $4,858,000 for the nine months ended September 30, 2008. The decrease in sales and marketing expenditures for both the third quarter and nine month periods ended September 30, 2009 as compared to the corresponding prior year pe
'/>"/>

SOURCE Cardiogenesis Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
2. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
3. Vion Pharmaceuticals Reports 2009 Third Quarter and Nine-Month Results
4. PLC Systems Reports Third Quarter 2009 Results; Announces Distribution Agreement for RenalGuard(R) in Brazil
5. Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results
6. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
7. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
8. Osteotech Reports Third Quarter 2009 Financial Results
9. Air Methods Reports 3Q2009 Results and 4Q2009 Update
10. Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009
11. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Virginia , 11. Juli 2014 ... von Kameras für die molekulare Bildgebung, ... hat heute die CE-Zulassung für sein ... CE-Zeichen kann Dilon das Produkt jetzt ... auf den Großteil der europäischen Länder ...
(Date:7/10/2014)... , July 10, 2014  RESMED INC. (NYSE: ... fourth quarter and fiscal year ended June 30, 2014 results ... Exchange market close. A press release with ResMed,s results will ... company will host a webcast to discuss operating results and ... begin at 1:30 p.m. US Pacific Time and the live ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... OncoSec Medical Incorporated (OTCBB:ONCS), which is developing ... to treat solid tumor cancers, today announced that ... and Lakeland Comprehensive Cancer Center in Lakeland, FL ... are screening patients for the Phase II metastatic ...
... International, Inc. (NASDAQ: BDSI ) announced that ... of further litigation in the patent infringement lawsuit previously ... that the case would be stayed pending resolution by ... proceedings and follows the recent rejection by the USPTO ...
Cached Medicine Technology:OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 2OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 4Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 2Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 3
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July ... HIV who was thought to be cured by immediate and ... levels of the AIDS-causing virus in her bloodstream, disappointed federal ... years old, had remained virus-free even though she stopped taking ... hoped her remission would open the door to a functional ...
(Date:7/11/2014)... Microbiology testing is a highly dynamic and rapidly ... expected to pose the biggest challenge to suppliers in ... to the ongoing spread of AIDS – still the ... factor leading to the upsurge of opportunistic infections, novel ... availability of immunosuppressants, among others. , Market maturity, ...
(Date:7/11/2014)... The report, “Specialty Synthetic Fibers & Glass ... 2018,” defines and segments the specialty synthetic fibers ... forecast of the volumes and values of types ... aramids, UHMW Polyethylene, carbon fiber, partially oxidized polyacrylonitrile ... PBO fiber, and liquid crystal polymer fiber and ...
(Date:7/11/2014)... 2014 Datalogic brings a new and ... hospital wide. With their new Gryphon GD4400 ... like the devastating MRSA, which claimed 5,500 lives, becomes ... 2D and the Gryphon GM4400-HC 2D readers can ... even read barcodes off of troublesome LCD monitors, smartphones, ...
(Date:7/11/2014)... 2014 Operators and owners ... in fuel costs now that model 2019 ... GHG standards are phasing in 2014-2018 ... themselves to install new features into their ... technologies , 2.    Efficient driveline components which reduce ...
Breaking Medicine News(10 mins):Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3
... on mountain biking it is observed that it could decrease ... Innsbruck, Austria,// presented his findings of a study that looked ... 30 non-bikers took part in the study. An extreme biker ... a day, six days a week, and more than 3,000 ...
... good coping style helps women to deal positively with breast ... a difference in the fight against cancer. Researchers in the ... that stress, mental outlook and coping style are all relevant ... ,They found that up to 44 per cent ...
... than conventional treatment for managing asthma attacks. Several ... cells known eosinophils increase// in the airways. Researchers ... targeting this build up of eosinophils in sputum ... attack. ,The conventional treatment consists of ...
... that doctors should use lower thresholds when treating high ... minorities.// Researchers at St George's Hospital, Georgia have carried ... of various ethnic origins, looking at their heart disease ... African origin have the lowest risk of heart disease, ...
... is observed that a drug used to treat inflammation ... meningitis. Dexamethasone is an effective steroid when given with ... diagnosed with bacterial meningitis is high, especially in patients ... Center in Amsterdam conducted a study to determine if ...
... According to a new study, researchers have observed that ... year after angioplasty had a decreased risk of problems. ... called a stent into a blocked coronary artery.// It's ... However, one complication that often occurs when such percutaneous ...
Cached Medicine News:
Alkaline phosphatase FS (DGKC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of alkaline phosphatase activity in serum or plasma. Kinetic reaction. 405 nm wavelength. 830 U/L at 30C linearity. Single vial, dry powder reagent....
Auto LDL-Cholesterol, automated analyzer test kits....
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
Medicine Products: